PIK3R1 anticorps (AA 15-180) (FITC)

N° du produit ABIN7154496

Détail du produit anti-PIK3R1 anticorps (FITC)

Antigène: PIK3R1 (PI3K p85a) (Phosphoinositide 3 Kinase, p85 alpha (PI3K p85a))

Épitope: AA 15-180

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PIK3R1 est conjugé à/à la FITC

Application: Veuillez nous consulter SVP

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Growth factor receptor-bound protein 10 protein (15-180AA)

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur PIK3R1

Antigène: PIK3R1 (PI3K p85a) (Phosphoinositide 3 Kinase, p85 alpha (PI3K p85a))

Autre désignation: GRB1 (PI3K p85a Produits)

Synonymes: anticorps PI3CG, anticorps PI3K, anticorps PI3Kgamma, anticorps PIK3, anticorps AGM7, anticorps GRB1, anticorps p85, anticorps p85-ALPHA, anticorps PI3KA, anticorps AA414921, anticorps C530050K14, anticorps p50alpha, anticorps p55alpha, anticorps p85alpha, anticorps wu:fb65b05, anticorps phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma, anticorps phosphoinositide-3-kinase regulatory subunit 1, anticorps phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta, anticorps phosphoinositide-3-kinase, regulatory subunit 1 (alpha), anticorps PIK3CG, anticorps PIK3R1, anticorps Pik3r1, anticorps Pik3cb, anticorps pik3r1

Sujet:

Background: Adapter protein which modulates coupling of a number of cell surface receptor kinases with specific signaling pathways. Binds to, and suppress signals from, activated receptors tyrosine kinases, including the insulin (INSR) and insulin-like growth factor (IGF1R) receptors. The inhibitory effect can be achieved by 2 mechanisms: interference with the signaling pathway and increased receptor degradation. Delays and reduces AKT1 phosphorylation in response to insulin stimulation. Blocks association between INSR and IRS1 and IRS2 and prevents insulin-stimulated IRS1 and IRS2 tyrosine phosphorylation. Recruits NEDD4 to IGF1R, leading to IGF1R ubiquitination, increased internalization and degradation by both the proteasomal and lysosomal pathways. May play a role in mediating insulin-stimulated ubiquitination of INSR, leading to proteasomal degradation. Negatively regulates Wnt signaling by interacting with LRP6 intracellular portion and interfering with the binding of AXIN1 to LRP6. Positive regulator of the KDR/VEGFR-2 signaling pathway. May inhibit NEDD4-mediated degradation of KDR/VEGFR-2.

Aliases: grb 10 antibody, GRB IR antibody, grb-10 antibody, GRB10 adapter protein antibody, GRB10 adaptor protein antibody, GRB10 antibody, GRB10_HUMAN antibody, GRBIR antibody, Growth factor receptor bound protein 10 antibody, Growth factor receptor-bound protein 10 antibody, Insulin receptor binding protein antibody, Insulin receptor binding protein GRB IR antibody, Insulin receptor-binding protein Grb-IR antibody, IRBP antibody, KIAA0207 antibody, Maternally expressed gene 1 antibody, MEG1 antibody, RSS antibody

UniProt: Q13322

Pathways: TCR Signaling, Response to Growth Hormone Stimulus, Regulation of Muscle Cell Differentiation, Skeletal Muscle Fiber Development, Hepatitis C, Protein targeting to Nucleus, VEGF Signaling, BCR Signaling, L'effet Warburg